SP-27 How Is Apical Periodontitis Influenced by Systemic Health and Medications? The Missing Link & SP-28 Mechanisms of Apical Periodontitis: Emergence of Epigenetic Regulators

5 (1 vote)

CE Credits: 1.5

SP-27 How Is Apical Periodontitis Influenced by Systemic Health and Medications? The Missing Link

It is widely-known that a correct endodontic treatment should take care of endodontic infection and promote healing of apical periodontitis. The general health of the patient affected by apical periodontitis, the medications taken, and the host predisposing factors, like genetics, have been very seldom considered when discussing the treatment and prognosis of apical periodontitis. The patient population requiring endodontic treatment is changing. Patients often suffer from a variety of pathologies and/or are under new categories of medications (like biologic drugs). Both these conditions influence the reactions and outcome of the treatment we perform. Some of these conditions and medications should be brought to the attention of the endodontist in order to enable him/her to alter the treatment and expectations consequently and to use new protocols when needed.

At the conclusion, participants should be able to:

  •  Discuss which is the impact of some common diseases and of the immune system on endodontic infection and vice-versa.
  •  Evaluate the interferences of immune-modulatory drugs and of drugs interfering with bone metabolism on the development and treatment of Endodontic infection.
  •  Evaluate the opportunity of using dedicated protocols for diagnosis and management of endodontic complications in medically compromised patients.

SP-28 Mechanisms of Apical Periodontitis: Emergence of Epigenetic Regulators

Endodontic therapies are in general highly successful and numerous outcomes studies indicate the success rates at 90 percent or higher. However, apical periodontitis (AP) continues to present challenge for endodontic therapies; AP is one of the most significant factor that hampers the outcome. Therefore, it is paramount to understand the mechanisms by which AP develops. Earlier studies utilized patient samples and animal models to determine the cellular and molecular factors that contribute to AP associated with root canal infection. These studies identified key cytokines and intracellular molecules that regulate the host inflammatory responses at root apex. At the higher level of regulation, recent studies underscore the importance of epigenetic modulators, e.g., histone methylatransferase and demethylases, that control the inflammatory and immune responses. This lecture will summarize the current knowledge of the mechanisms underlying AP and present the emerging role of epigenetic regulators that determine inflammatory and immune responses.

At the conclusion, participants should be able to:

  •  Explain the importance of AP in the outcomes of endodontic therapies.
  •  Describe the current mechanism of AP involving inflammatory mediators and key cytokines that play the major roles.
  •  Describe the role of epigenetic regulation in control of gene expression; key epigenetic modulators that may regulate the expression of inflammatory cytokines involved in AP.

Key:

Complete
Failed
Available
Locked
SP-27 How Is Apical Periodontitis Influenced by Systemic Health and Medications? The Missing Link
MP3 Audio
Open to listen to or download MP3 audio.
Open to listen to or download MP3 audio.
Presentation
Open to view video.
Evaluation
7 Questions
CE Test
5 Questions  |  Unlimited attempts  |  4/5 points to pass
5 Questions  |  Unlimited attempts  |  4/5 points to pass
SP-28 Mechanisms of Apical Periodontitis: Emergence of Epigenetic Regulators
MP3 Audio
Open to listen to or download MP3 audio.
Open to listen to or download MP3 audio.
Presentation
Open to view video.
Evaluation
7 Questions
CE Test
5 Questions  |  Unlimited attempts  |  4/5 points to pass
5 Questions  |  Unlimited attempts  |  4/5 points to pass
Certificate
1.50 CE credits  |  Certificate available
1.50 CE credits  |  Certificate available

Elisabetta Cotti, D.D.S., M.S.

I am graduated in Dentistry at the University of Cagliari in 1985; I am specialized in Endodontics in 1990 and Master of Science in Endodontics in 1991 at the University of Loma Linda --California. I am an 'Associate Professor of Conservative Dentistry and Endodontics at the University of Cagliari where I direct the Department of Conservative and Endodontics. I teach in the Master of Endodontics at the University of Bologna and Cagliari. I am an 'active member of the American Association of Endodontists (AAE) where I was the international representative from 2000 to 2006; Director of SIE from 1993 to 2003, the European Association of Endodontology (ESE) where I was Representative for Italy from 1997 to 2003. Private practice limited to endodontics, I am the author of national and international work in the field of endodontics.


Mo Kang, D.D.S., M.S., Ph.D.

SP-7 Minced Pulp Tissue as Source of Pulpal MSCs

Dr. Kang is Professor and Chairman of the Section of Endodontics at the UCLA School of Dentistry. He holds Jack Weichman Endowed Chair at UCLA. Dr. Kang received his DDS and PhD from UCLA in 2001 and completed his endodontic training there in 2003. He has received numerous honors for his research and scholarship, including the Edward E. Hatton award from the American and International Association for Dental Research and distinguished scientist awards. Dr. Kang’s research focuses on the mechanisms of pulpal inflammation, tissue regeneration, as well as cancer biology. He currently serves as Associate Editor of the Journal of Endodontics and review board for Journal of Dental Research. Dr. Kang is an internationally recognized scholar and lecturer with his expertise in clinical endodontics, bioceramics, pulp regeneration, and other basic science topics. He maintains active private practice limited to Endodontics.

Elisabetta Cotti, D.D.S., M.S.

I declare that I have no proprietary, financial, or other personal interest of any nature or kind in any product, service, course, and/or company, or in any firm beneficially associated therewith, that will be discussed or considered during the proposed presentation.

Mo Kang, D.D.S., M.S., Ph.D.

I declare that I have no proprietary, financial, or other personal interest of any nature or kind in any product, service, course, and/or company, or in any firm beneficially associated therewith, that will be discussed or considered during the proposed presentation.